In its effort to increase competition in the prescription drugs market and facilitate the entry of lower-cost alternatives, today the FDA published a list of branded drugs (based on the Orange Book Data Files) that have no listed patents or exclusivities and for which the agency has yet to approve a generic drug application. The[…]